PA173144
Neisseria gonorrhoeae Polyclonal Antibody, HRP, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PA173144-Each-of-1 | In Stock | ₹ 45,968.50 |
PA173144 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 45,968.50
GST (18%): ₹ 8,274.33
Total Price: ₹ 54,242.83
Antigen
Neisseria gonorrhoeae
Classification
Polyclonal
Conjugate
HRP
Gene Alias
Gonococci; N. gonorrhoeae
Immunogen
Whole N. gonorrhoeae; ATCC 31426.
Quantity
1 mL
Primary or Secondary
Primary
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
ELISA, Immunohistochemistry, Western Blot
Concentration
1-2 mg/mL
Formulation
PBS with 10mg/mL BSA and 0.002% thimerosal, pH 7.2
Host Species
Rabbit
Purification Method
IgG fraction
Regulatory Status
RUO
Target Species
Bacteria
Product Type
Antibody
Isotype
IgG
Related Products
Description
- The PA1-73144 antibody reacts with Neisseria gonorrhoeae
- PA1-73144 has been successfully used in ELISA, IHC, and IB applications
- The PA1-73144 antibody was raised against whole N
- gonorrhoeae; ATCC 31426
- Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide
- Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually
- Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid
- The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness
- Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases
- Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus
- Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.